RNAi therapeutics for CNS disorders

被引:35
|
作者
Boudreau, Ryan L. [1 ]
Davidson, Beverly L. [1 ,2 ]
机构
[1] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Neurol, Iowa City, IA 52242 USA
关键词
RNAi; Therapy; Neurodegenerative; Huntington's; Alzheimer's; Parkinson's; Ataxias; DOUBLE-STRANDED-RNA; SMALL INTERFERING RNA; POLYGLUTAMINE-INDUCED NEURODEGENERATION; HUNTINGTONS-DISEASE; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; PROLONGS SURVIVAL; MUTANT SOD1; TRANSGENIC MICE; GENE-EXPRESSION;
D O I
10.1016/j.brainres.2010.03.038
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
RNA interference (RNAi) is a process of sequence-specific gene silencing and serves as a powerful molecular tool to manipulate gene expression in vitro and in vivo. RNAi technologies have been applied to study gene function and validate drug targets. Researchers are investigating RNAi-based compounds as novel therapeutics to treat a variety of human diseases that are currently lacking sufficient treatment. To date, numerous studies support that RNAi therapeutics can improve disease phenotypes in various rodent models of human disease. Here, we focus on the development of RNAi-based therapies aimed at treating neurological disorders for which reduction of mutant or toxic gene expression may provide clinical benefit. We review RNAi-based gene-silencing strategies, proof-of-concept studies testing therapeutic RNAi for CNS disorders, and highlight the most recent research aimed at transitioning RNAi-based therapeutics toward clinical trials. (C) 2010 Elsevier B.V. All rights reserved.
引用
收藏
页码:112 / 121
页数:10
相关论文
共 50 条
  • [1] Nanotechnology—novel therapeutics for CNS disorders
    Maya Srikanth
    John A. Kessler
    Nature Reviews Neurology, 2012, 8 : 307 - 318
  • [2] Nanotechnology-novel therapeutics for CNS disorders
    Srikanth, Maya
    Kessler, John A.
    NATURE REVIEWS NEUROLOGY, 2012, 8 (06) : 307 - 318
  • [3] RNAi therapeutics
    Limmer, S
    JOURNAL OF BIOTECHNOLOGY, 2005, 118 : S69 - S69
  • [4] Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders
    Guo, Zi-Hua
    Khattak, Saadullah
    Rauf, Mohd Ahmar
    Ansari, Mohammad Azam
    Alomary, Mohammad N.
    Razak, Sufyan
    Yang, Chang-Yong
    Wu, Dong-Dong
    Ji, Xin-Ying
    MOLECULES, 2023, 28 (03):
  • [5] The business of RNAi therapeutics
    Haussecker, Dirk
    HUMAN GENE THERAPY, 2008, 19 (05) : 451 - 462
  • [6] The world of RNAi therapeutics
    Manoharan, M.
    FEBS OPEN BIO, 2019, 9 : 50 - 50
  • [7] RNAi therapeutics delivered
    Manoharan, Muthiah
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [8] Targeted protein degradation in CNS disorders: a promising route to novel therapeutics?
    Kuemper, Sandra
    Cairns, Andrew G.
    Birchall, Kristian
    Yao, Zhi
    Large, Jonathan M.
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2024, 17
  • [9] Biomimetic chemistry of RNAi therapeutics
    Manoharan, Muthiah
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 257
  • [10] RNAi Therapeutics Gaining Ground
    Liszewski, Kathy
    GENETIC ENGINEERING & BIOTECHNOLOGY NEWS, 2010, 30 (07): : 22 - 23